Ventyx Biosciences, Inc. Logo

Ventyx Biosciences, Inc.

Develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases.

VTYX | US

Overview

Corporate Details

ISIN(s):
US92332V1070
LEI:
Country:
United States of America
Address:
12790 EL CAMINO REAL, SUITE 200, 92130 SAN DIEGO

Description

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company utilizes its expertise in medicinal chemistry, structural biology, and immunology to discover and advance differentiated small molecule therapeutics for conditions with high unmet medical needs. Its clinical pipeline features a portfolio of NLRP3 inhibitors, including VTX2735, a peripherally restricted candidate in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant candidate in Phase 2 for neurodegenerative and cardiometabolic diseases. Additionally, its inflammatory bowel disease portfolio includes tamuzimod, an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Ventyx Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ventyx Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ventyx Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.